Insider Selling: Billiontoone (NASDAQ:BLLN) Insider Sells 2,832 Shares of Stock

Billiontoone, Inc. (NASDAQ:BLLN) insider Bosch John Roderick Ten sold 2,832 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $101.47, for a total value of $287,363.04. Following the transaction, the insider directly owned 34,968 shares in the company, valued at $3,548,202.96. This trade represents a 7.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Billiontoone Trading Down 1.3%

Shares of BLLN stock traded down $1.32 on Wednesday, hitting $99.38. 963,691 shares of the stock traded hands, compared to its average volume of 453,406. The firm’s 50-day moving average price is $88.95 and its two-hundred day moving average price is $87.60. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.58 and a current ratio of 10.92. The stock has a market capitalization of $4.57 billion and a PE ratio of 180.69. Billiontoone, Inc. has a twelve month low of $61.96 and a twelve month high of $138.70.

Billiontoone (NASDAQ:BLLN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.33. The firm had revenue of $108.39 million for the quarter, compared to analyst estimates of $95.81 million. During the same period in the previous year, the firm posted ($0.39) EPS. The company’s revenue was up 83.8% compared to the same quarter last year. As a group, analysts anticipate that Billiontoone, Inc. will post 0.93 EPS for the current year.

Institutional Trading of Billiontoone

A number of hedge funds and other institutional investors have recently bought and sold shares of BLLN. Rossby Financial LCC acquired a new stake in Billiontoone in the fourth quarter valued at $25,000. Wells Fargo & Company MN acquired a new stake in shares of Billiontoone during the 4th quarter worth about $76,000. Smartleaf Asset Management LLC acquired a new stake in shares of Billiontoone during the 4th quarter worth about $80,000. Nano Cap New Millennium Growth Fund L P acquired a new stake in shares of Billiontoone during the 4th quarter worth about $82,000. Finally, Renaissance Capital LLC acquired a new stake in shares of Billiontoone during the 4th quarter worth about $201,000.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. JPMorgan Chase & Co. upped their target price on shares of Billiontoone from $120.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Guggenheim upped their price objective on shares of Billiontoone from $100.00 to $120.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th. Wells Fargo & Company decreased their price target on Billiontoone from $110.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 5th. Weiss Ratings cut Billiontoone from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 5th. Finally, BTIG Research decreased their price target on Billiontoone from $140.00 to $130.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Six investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $125.29.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.